Hyperpigmentation following Treatment of Frontal Fibrosing Alopecia by Pérez Rodríguez, Irma Margarita et al.
 Case Rep Dermatol 2013;5:357–362 
DOI: 10.1159/000357022 
Published online: November 23, 2013 
© 2014 S. Karger AG, Basel 
1662‒6567/14/0053‒0357$39.50/0 
www.karger.com/cde 
This is an Open Access article licensed under the terms of the Creative Commons 
Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-
license), applicable to the online version of the article only. Distribution permitted for non-
commercial purposes only. 
 
 
            Irma Margarita Pérez-Rodríguez, MD 
Department of Dermatology, Hospital Universitario ‘Dr. José Eleuterio González ’ 
Avenida Madero y Gonzalitos s/n, Col. Mitras Centro 
Monterrey 64460 (Mexico) 
E-Mail dra.irma.perez@gmail.com 
 
 
 
Hyperpigmentation following 
Treatment of Frontal Fibrosing 
Alopecia 
Irma Margarita Pérez-Rodríguez    Martha Elena García-Melendez    
Kristian Eichelmann    Osvaldo Vázquez-Martínez    Jorge Ocampo-
Candiani  
Department of Dermatology, Hospital Universitario ‘Dr. José Eleuterio González’, 
Universidad Autónoma de Nuevo León, Monterrey, Mexico 
Key Words 
Hyperpigmentation · Frontal fibrosing alopecia · Scarring alopecia 
Abstract 
Introduction: Frontal fibrosing alopecia (FFA) is a scarring alopecia characterized by 
progressive recession of the frontotemporal hairline. Current treatment is aimed at stopping 
progression, and the combination of dutasteride and pimecrolimus is the most effective 
therapy. Side effects associated with dutasteride are erectile dysfunction as well as breast 
tenderness and enlargement, while pimecrolimus produces a burning sensation. Case 
Report: We present a 57-year-old postmenopausal female with a 3-year history of a scarring 
alopecic plaque in her frontotemporal region. Biopsy confirmed the diagnosis of FFA, and 
she was started on dutasteride 0.5 mg p.o. q.d., and later, topical pimecrolimus 1% b.i.d. was 
added. Eight months after initiating treatment, she showed hyperpigmentation on her 
metacarpophalangeal and interphalangeal joints, as well as on the cheeks and on the chin; 
dutasteride and pimecrolimus were discontinued. After 5 months of follow-up, her hyper-
pigmentation improved by 80% only by using photoprotection. Conclusion: Because of the 
variable clinical course of FFA, treatment is focused on halting its progression. Several 
therapeutic agents have been evaluated and the combination of dutasteride and pimecroli-
mus has shown a high response rate. There is no reported evidence of hyperpigmentation 
associated with this combination. © 2014 S. Karger AG, Basel 
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Introduction 
Frontal fibrosing alopecia (FFA) is a scarring alopecia that affects postmenopausal 
women and is considered a clinical variant of lichen planopilaris. Classic symptoms include 
erythema, follicular hyperkeratosis and progressive recession of the frontotemporal hairline 
[1]. Currently, there is no treatment of choice and because of the scarring nature, the aim is 
to stop progression. Studies have shown that the combination of dutasteride and pimecroli-
mus is by far the most effective therapy for this condition, and even hair regrowth has been 
reported [2, 3]. 
Case Report 
We present a 57-year-old postmenopausal female with a 3-year history of scarring 
alopecic plaques on both her frontotemporal regions, which she developed after an upper 
third face lift with aptos threads. Dermoscopy showed an absence of follicular openings, 
perifollicular scaling and erythema. Skin biopsy revealed the presence of a perifollicular 
lymphocytic infiltrate and lamellar fibrosis, a decrease of hair follicles and apoptotic cells in 
the external root sheath, therefore confirming the diagnosis of FFA (fig. 1). 
Treatment was started with dutasteride 0.5 mg p.o. q.d. At the fifth month of follow-up, 
we added topical pimecrolimus 1% b.i.d. At this point, the patient presented a 40% 
improvement in erythema and even showed slight hair regrowth. 
Eight months after the treatment was started, the patient presented hyperchromic 
macules in the metacarpophalangeal and interphalangeal joints of both hands as well as on 
the cheeks and chin (fig. 2); she denied the use of other concomitant treatments. A skin 
biopsy was performed, revealing basal layer membrane hyperpigmentation.  
Treatment was stopped and the use of photoprotection was encouraged. Five months 
after the treatment was discontinued, the patient showed an 80% improvement of her 
hyperpigmented lesions (fig. 3). 
Discussion 
FFA was described in 1994 by Kossard in postmenopausal women, but it can also affect 
premenopausal women and males. It is considered a clinical variant of lichen planopilaris; 
histologically, both entities show a lymphocytic infiltrate and fibrosis between the follicular 
epithelium and the dermis, involving the upper mid-portion of the follicle, but FFA shows 
less inflammatory infiltrate than lichen planopilaris [4]. The pathogenesis is unknown, but a 
T-cell-mediated inflammatory reaction with the destruction of stem cells and hormonal 
changes as well as increased levels of androgens are thought to play an important role [5]. 
FFA has a variable clinical course and the treatment is focused on stopping progression. 
Several therapeutic agents have been evaluated and topical and systemic corticosteroids 
have been the most commonly used agents; with a high risk of relapse upon discontinuation 
[1], other treatments have been studied, e.g. antimalarials, mycophenolate mofetil, 
doxycycline, and topical minoxidil with variable results [2]. 
Treatments with 5α-reductase inhibitors have shown good results supporting the role of 
androgens in the pathogenesis of FFA [6]. Dutasteride is a 5α-reductase inhibitor, it is 3 
times more potent than finasteride at inhibiting type II enzyme and 100 times more potent 
at inhibiting type I enzyme, making it a leading option in treating FFA. 
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Pimecrolimus, a topical calcineurin inhibitor that blocks T-cell activation and cytokine 
production, has been used effectively in combination with dutasteride [3]. 
Reported side effects associated with dutasteride and finasteride use are erectile dys-
function as well as breast tenderness and enlargement [7, 8]. For finasteride, there are 
reports of cutaneous vasculitis, drug-related folliculitis, erythema annulare centrifugum, 
solitary fixed drug eruption, urticarial rash and acute generalized exanthematous pustulosis; 
the last one occurred 3 months after it was initiated [9]. For pimecrolimus, the reported 
adverse effects are a burning sensation and pruritus [8], and there is one report of induced 
lentiginosis on the application site of this drug [10]; however, in this case, the hyperpigmen-
tation did not appear at the sites of application of pimecrolimus. There is no reported 
evidence of hyperpigmentation associated with this combination or with the use of 
dutasteride. 
Another described cause of hyperpigmentation in the presence of alopecia is the 
Cronkhite-Canada syndrome. It is a rare syndrome involving the skin and the gastrointesti-
nal tract, showing hyperpigmentation, alopecia, onychodystrophy, diarrhea, hamartomatous 
polyposis and weight loss [11, 12]. An autoimmune mechanism may be involved, but the 
etiopathogenesis remains unknown [12]. 
Initial symptoms are diarrhea and dysgeusia, and the dermatologic triad occurs later 
[12]. The alopecia in these patients is a non-scarring alopecia, with telogen hair follicles 
without miniaturization or atrophy of the hair follicle and absence of inflammation [13], 
which can start in patches and then become total; the hyperpigmentation is observed 
diffusely in the upper extremities. It shows onychodystrophy which includes a thinning of 
the nail plate, onycholysis and onychomadesis [11]. 
In our patient’s case, this diagnosis is discarded because she does not have gastrointes-
tinal symptoms, she has a scarring alopecia, and the hyperpigmentation occurred mainly on 
her face. 
Conclusion 
Because of the variable clinical course of FFA, treatment is focused on halting its pro-
gression. Several therapeutic agents have been evaluated; the combination of dutasteride 
and pimecrolimus has shown a high response rate. This case is of particular interest because 
the patient developed hyperpigmentation following the use of dutasteride and a remission 
after its discontinuation. There is still no clear evidence that points to dutasteride as the sole 
precipitating agent; therefore, more studies are required to further evaluate this association. 
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Fig. 1. a–d Female patient with frontotemporal hairline recession. e Histologic image showing lamellar 
fibrosis. f Dermoscopic image showing erythema, absence of follicular openings and perifollicular scaling. 
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Fig. 2. Eight-month follow-up; the patient presents hyperchromic macules in metacarpophalangeal and 
interphalangeal joints, cheeks and chin. 
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Fig. 3. Five months after treatment suspension, improvement in the lesions can be observed. 
 
